# Fulminant multi-organ myositis as a rare immune-related adverse event of nivolumab–relatlimab (Opdualag) therapy in metastatic melanoma: a case report

## TL;DR

A rare and severe immune-related side effect of Opdualag treatment in a melanoma patient led to multi-organ myositis and ultimately death.

## Contribution

First published report of fulminant multi-organ myositis as a rare adverse event of Opdualag therapy.

## Key findings

- Patient showed marked antitumor response to Opdualag before developing severe myositis.
- Fulminant myositis with multi-organ involvement occurred as a late-onset immune-related adverse event.
- Despite aggressive treatment, the patient succumbed to the complications of the adverse event.

## Abstract

Immune checkpoint inhibitors (ICIs) have transformed the management of metastatic melanoma, providing durable survival benefits in a subset of patients. However, their use is associated with immune-related adverse events (irAEs), which may be unpredictable, severe, and occasionally fatal. We describe the case of a 77-year-old man with metastatic melanoma treated with nivolumab plus relatlimab (Opdualag), who achieved a marked antitumor response after seven treatment cycles. He subsequently developed fulminant late-onset myositis with multi-organ involvement, representing a particularly severe and atypical presentation. Despite timely recognition and aggressive immunosuppressive therapy, the clinical course was unfavorable, and the patient ultimately succumbed to these complications. To the best of our knowledge, this is the first published report of such a rare and fulminant multi-organ presentation of Opdualag-associated myositis. This report highlights the importance of vigilance for delayed and life-threatening irAEs and underscores the need for interdisciplinary collaboration and structured monitoring protocols as novel ICI combinations enter routine clinical practice.